Domus Diagnostics is pioneering a novel approach to diagnostic testing by integrating advanced custom chemistry with straightforward manufacturing techniques. Their proprietary RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification) technology is designed to deliver high-performance, low-cost solutions for infectious disease testing. This one-step, one-temperature method allows for the development of tests that are not only accurate—boasting over 95% sensitivity and 100% specificity—but also rapid, providing results in 30 minutes or less. The company’s flagship product is an at-home, disposable test that requires no electricity, making it accessible for use in both developed and developing regions.

The Domus Molecular Testing Platform is characterized by its flexibility and ease of use, enabling the testing of a single sample for multiple targets, including the differentiation of various respiratory viruses. The design is intentionally simple, utilizing low-cost materials and a self-contained, disposable format that eliminates the need for batteries or complex machinery. This innovative approach allows for scalable manufacturing and affordability, with a cost of goods sold (COGS) as low as $4 for multi-target tests. Domus Diagnostics aims to make high-quality diagnostic testing accessible globally, positioning itself as a leader in the market through its commitment to performance, simplicity, and cost-effectiveness.

United States

Domus Diagnostics is working to create infectious disease diagnostic tests that are affordable, user-friendly, accurate, and rapid enough to address the needs raised by current and future public health crises.

Domus Diagnostics

Company Details